Description
Nintedanib capsules received initial U.S. approval in 2014. It’s indicated as a kinase inhibitor for:
-
- Idiopathic pulmonary fibrosis (IPF).
- Chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
- To slow pulmonary function decline in systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Dosage and Side Effects of Nintedanib Capsules
The recommended dosage involves taking 150 mg of Nintedanib Capsule twice daily, approximately 12 hours apart with food. Adjustments are necessary for patients with mild hepatic impairment, requiring 100 mg twice daily. Temporary dose reduction, treatment interruption, or discontinuation might be necessary for managing adverse reactions. Liver function tests and pregnancy tests for females of reproductive potential should be conducted before treatment initiation.Â
Common adverse reactions include diarrhea, nausea, abdominal pain, vomiting, liver enzyme elevation, decreased appetite, headache, weight decrease, and hypertension.
Warning and Precautions of Nintedanib Capsules
- Patients with significant liver problems should avoid this medication or seek guidance from a healthcare provider. Adjustments in dosage might be necessary for individuals with mild liver impairment.
- Females planning to conceive should avoid this medication due to potential harm to fertility. It’s advisable not to use this medication while breastfeeding.
- Prior to starting Nintedanib, discuss your medical history and family medical background with your healthcare professional.
- If allergic to this medication or its components, refrain from taking it without consulting a pharmacist or healthcare provider.
- Patients with a history of gastrointestinal surgeries or certain gastrointestinal conditions should exercise caution. Discontinue the medication if gastrointestinal perforation occurs.
